Europe Continuous Glucose Monitoring Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2030)

Europe Continuous Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence in Europe

Europe's continuous glucose monitoring market momentum is anchored by 65.6 million adults currently living with diabetes, a figure projected to climb to 72.4 million by 2050^{[1]International Diabetes Federation, “IDF Diabetes Atlas 11th Edition,” idf.org} . Younger onset of Type 2 diabetes in Eastern Europe widens the addressable patient pool beyond the historical Type 1 focus. German cohort studies show HbA1c improvements to 7.13% among CGM users versus 7.66% for non-users, strengthening physician confidence. Endocrinologists increasingly prescribe CGM at diagnosis rather than after finger-stick failure, embedding the technology as first-line management. This epidemiological tailwind sustains the Europe continuous glucose monitoring market even during economic slowdowns.

Expansion of Reimbursement for CGM Devices

Statutory coverage in Germany since 2016, France’s broadened Assurance Maladie listing in 2024, and NHS England’s FreeStyle Libre program collectively remove upfront cost barriers. Reimbursed users scan glucose 16.3 times per day compared with 4–6 finger-stick tests. Predictable payouts foster manufacturer pipeline investment and scale production. Italy and Spain mirror the policy path through regional tenders, creating a domino effect across Southern Europe. The reimbursement wave underpins double-digit revenue visibility for the Europe continuous glucose monitoring market through 2030.

Advances in User-Friendly Wearable Sensors

Calibration-free designs, smartphone pairing, and AI-powered trend warnings increase adherence. Roche’s machine-learning CGM obtained CE Mark in 2024, offering automated dosing suggestions^{[2]Roche Holding AG, “Roche Receives CE Mark for New CGM System,” roche.com} . Medtronic’s Simplera Sync extends wear to 7 days without finger-stick calibration. Dexcom and Abbott target 100 million annual sensor output from Irish lines by 2027, aiming to cut unit cost by 25-30%. These innovations strengthen patient loyalty and attract first-time adopters, solidifying Europe's continuous glucose monitoring market footprint.

Telehealth-Driven Demand for Remote Monitoring

EU health systems invested EUR 2.3 billion in digital platforms during 2024, embedding CGM feeds into clinician dashboards. German diabetes centers report 40% fewer emergency visits among tele-monitored patients. Remote review saves clinician time and hospitals’ operational budgets, accelerating contract renewals. National EHR programs in Germany, France, and the Netherlands standardize CGM data uploads, reinforcing the Europe continuous glucose monitoring market’s digital-first evolution.

High Device Cost and Partial Reimbursement Gaps

Income disparities across Eastern Europe keep patient co-pays high. Some Italian southern regions still reimburse only 70% of sensor cost, stalling uptake. Local advocacy groups lobby for full coverage, but budget constraints prolong negotiations. Manufacturers deploy patient-assistance vouchers yet struggle to close affordability gaps quickly. These pockets temper volume growth within the Europe continuous glucose monitoring market until broader funding parity is secured.

Sensor Accuracy and Calibration Concerns

Hospital adoption lags due to worries about accuracy during rapid glycemic swings. Only 16.7% of UK trusts have formal inpatient CGM guidelines. Clinical teams cite dose-critical decisions and interference risks. Training modules and new algorithms that self-adjust for perfusion changes are entering trials. Until results convince institutional committees, the Europe continuous glucose monitoring market faces speed bumps in the acute-care segment.

Segment Analysis

By Component: Sensors Drive Market Expansion

Sensors accounted for 82.21% of 2024 revenue within the Europe continuous glucose monitoring market, reflecting their consumable nature and 14-day replacement cycles. Segment growth is forecast at a 15.68% CAGR through 2030 as extended-wear versions such as Senseonics’ 6-month Eversense E3, approved in 2024, gain traction. Automated Irish production lines from Dexcom and Abbott are expected to lift annual capacity to 100 million units by 2027, pushing unit cost below EUR 30 and spurring use in lower-income regions. Receivers and transmitters held 17.79% share but shift toward smartphone apps is gradually eroding dedicated hardware sales. Software subscriptions that interpret CGM data emerge as a fresh margin pool, diversifying revenue beyond physical sensors. Interoperability standards embedded in the EU-MDR encourage app-centered ecosystems and third-party analytics, a trend that deepens platform lock-in for the Europe continuous glucose monitoring market.  

Note: Segment shares of all individual segments available upon report purchase

By End User: Home Personal Use Dominates

Home/personal users represented 72.24% of the Europe continuous glucose monitoring market share in 2024 and are projected to sustain a 15.20% CAGR through 2030. The shift reflects patient desire for autonomy, real-time smartphone alerts, and telemedicine consults that cut clinic travel. Hospitals and clinics, with 27.76% share, nevertheless show a 15.72% CAGR as infection-control protocols adopted during COVID-19 normalize sensor use in wards. UK data show a 23% reduction in inpatient hypoglycemia where CGM is standard. Capital budgets now favor CGM over intermittent finger-stick monitors because nursing workload drops and length of stay decreases. Workflow integration modules added to electronic medical records mitigate earlier calibration concerns and advance hospital penetration across the Europe continuous glucose monitoring market.  

By Demography: Pediatric Segment Shows Fastest Growth

Adults comprise 62.73% of 2024 revenue, but pediatric users—holding 37.27%—clock the fastest 15.79% CAGR through 2030. Updated ISPAD guidelines mandate CGM as standard for children, and reimbursement regimes in Germany cover 95% of pediatric costs. Adoption exceeds 85% among newly diagnosed children, compared with 60% among adults, underscoring the generational tech embrace that will shape long-run demand. Rising adolescent Type 2 incidence in Eastern Europe widens the pool further. Parental demand for remote alerts and school-day oversight adds a use-case advantage that finger-stick meters cannot match. Device makers tailor adhesive strength, app graphics, and tiny gauge wires to safeguard sensitive skin. Pediatric-centric user interfaces encourage self-management earlier in life, anchoring lifetime loyalty within the Europe continuous glucose monitoring market. As these children age into adulthood, replacement cycles lengthen yet unit volumes stay high, ensuring a durable growth pillar for the Europe continuous glucose monitoring market.

Geography Analysis

Germany generated 22.56% of 2024 revenue in the Europe continuous glucose monitoring market and is forecast to post the region’s highest 17.07% CAGR through 2030. The country’s 1,000-plus diabetes centers, generous statutory coverage, and rapid telehealth maturity position it as the innovation proving ground. France followed at 17.39% share and a 16.29% CAGR as Assurance Maladie broadened indications and domestic majors such as Sanofi championed national procurement alliances. The United Kingdom held a 16.21% stake; NHS coverage for FreeStyle Libre offsets Brexit-related regulatory divergence, maintaining steady device volumes.

Italy accounted for 12.44% of Europe's continuous glucose monitoring market size in 2024 and should compound at 15.15% as regional funding gaps shrink. Spain’s 9.88% share and 13.61% CAGR reflect decentralized reimbursement that is gradually synchronizing with national diabetes plans. Russia captured a 9.36% share; sanctions and currency pressure trim growth to 11.64% yet local assembly projects could redirect supply lines.

The rest of Europe comprised 12.15% revenue with a 14.09% CAGR. Poland, the Czech Republic, and Hungary demonstrate outsized momentum as EU cohesion funds underwrite digital health rollouts. Nordic countries, although smaller in population, post near-universal sensor usage due to comprehensive social healthcare and digital record parity. Collectively, rising penetration across Eastern states offsets mature base effects in Western Europe, reinforcing the long-term resilience of the Europe continuous glucose monitoring market.